Clinical trials for Gastroesophageal junction adenocarcinoma investigate a range of treatment strategies and patient populations.

17 total trials for this combination

Showing top 10 of 17 trials

Trials

NCT ID	Title	Status	Phase
NCT03170960	Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	ACTIVE_NOT_RECRUITING	PHASE1
NCT03604991	Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery	SUSPENDED	—
NCT06157892	A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors	RECRUITING	PHASE2
NCT07431281	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2	RECRUITING	PHASE3
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	RECRUITING	PHASE1/PHASE2
NCT03604991	Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery	SUSPENDED	—
NCT04152499	Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)	ACTIVE_NOT_RECRUITING	PHASE1/PHASE2
NCT04208958	Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer	COMPLETED	PHASE1/PHASE2
NCT01196390	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	COMPLETED	PHASE3
NCT06764875	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer	RECRUITING	PHASE3

Related Pages

All Gastroesophageal junction adenocarcinoma trials All trials in Dallas, United States